Includes bibliographical references and index.

Targeted therapy for metastatic renal call carcinoma: overview -- Molecular genetics in inherited renal cell carcinoma: identification of targets in the hereditary syndromes -- Molecular targets in renal tumors: pathologic assessment -- Interferons and interleukin-2: molecular basis of activity and therapeutic results -- The molecular biology of kidney cancer and its clinical translation into treatment strategies -- VEGF: biologic aspects and clinical approaches -- VEGF and PDGF receptors: biologic relevance and clinical approaches to inhibition -- Sunitinib and axitinib in renal cell carcinoma -- Sorafenib in renal cell carcinoma -- Additional tyrosine kinase inhibitors in renal cell carcinoma -- Integrin [alpha]5[beta]1 as a novel therapeutic target in renal cancer -- Carbonic anhydrase IX: biology and clinical approaches -- Monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma: biological and clinical studies -- Chemokines in renal cell carcinoma: implications for tumor angiogenesis and metastasis -- P13K/Akt/mTOR pathway: a growth and proliferation pathway -- EGFR and HER2: relevance in renal cell carcinoma -- Proteasome-NF[kappa]B signaling pathway: relevance in RCC -- The role of hepatocyte growth factor pathway signaling in renal cell carcinoma -- Smac/DIABLO: a proapoptotic molecular target in renal cell cancer -- EphA2: a novel target in renal cell carcinoma -- Restoring host antitumoral immunity: how coregulatory molecules are changing the approach to the management of renal cell carcinoma -- The role of gangliosides in renal cell carcinoma -- Tumour necrosis factor: misnomer and therapeutic target -- Molecular markers for predicting prognosis of renal cell carcinoma -- Adjuvant therapy for renal cell carcinoma: targeted approaches.